Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Dianthus Therapeutics. The associated price target remains the same with $65.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Rami Katkhuda has given his Buy rating due to a combination of factors surrounding Dianthus Therapeutics’ recent strategic moves and the potential of its pipeline. The company’s exclusive in-license agreement with Leads Biolabs for DNTH212, a first-in-class BDCA2 and BAFF/APRIL inhibitor, is a significant development. This treatment offers a dual targeting mechanism that could enhance efficacy across multiple autoimmune indications by modulating both innate and adaptive immune systems. The innovative design of DNTH212, including its YTE-modified Fc for self-administration and potential for less frequent dosing, adds to its attractiveness.
Moreover, the planned Phase I study in China and expected data from healthy volunteers in 2026 are key upcoming catalysts. These developments, alongside other internal and external catalysts such as the progress of claseprubart in CIDP and MMN, strengthen Dianthus’ position in the market. The company’s robust pipeline and strategic partnerships suggest a promising outlook, justifying the Buy recommendation by Rami Katkhuda.
According to TipRanks, Katkhuda is a 5-star analyst with an average return of 29.9% and a 52.97% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Dianthus Therapeutics, MoonLake Immunotherapeutics, and Viridian Therapeutics.
In another report released on October 14, Truist Financial also initiated coverage with a Buy rating on the stock with a $56.00 price target.